|Christopher Morris, PhD - Interim Chief Executive Officer|
Mr. Morris has more than 12 years of experience in the finance industry including senior roles in corporate finance, capital markets, and restructuring initiatives. Mr. Morris is founder and President of R.C. Morris & Company, which provides various financial, advisory and consulting services to companies, investors and executives, and has previously held several senior executive roles in both private and public companies. Mr. Morris holds a PhD from Cambridge University.
|Dr. John Husnik, PhD - Chief Technology & Innovation Officer|
Dr. Husnik is responsible for Functional Technologies' core technology platforms as well as new innovations, utilizing his experience in driving R&D assets from bench to commercialization. He will continue to lead the Company's food science research teams in advancing, expanding and testing its proprietary technologies, protocols associated with industry partner (e.g. large food companies)-driven collaborations, and optimizing as well as extending existing product portfolios. His expertise has enabled Dr. Husnik to contribute substantially to the cultivation and advancement of Functional Technologies' core yeast platforms that provide superior functionality and solutions to critical problems in global food and beverage sectors. These activities have and will continue to be facilitated by Dr. Husnik's strong scientific background over 18 years, including extensive experience encompassing a variety of techniques associated with classical yeast strain improvement as well as novel and innovative solutions that enhance native traits of yeasts and other industry-relevant microorganisms. Dr. Husnik received his PhD from the University of British Columbia and his MSc as well as BSc from the University of Guelph. His graduate study work combined with his years in the field working for Functional Technologies in development, testing and product trialing with some of the largest food companies in the world, provide him with critical skill sets for innovation and practical management knowledge in managing these programs, yielding practical and relevant results toward adoption of proprietary products in the global marketplace.
|Connie Chen, PhD - Vice President, Corporate Development and Communications|
Dr. Chen joined Functional Technologies Corp. with over five years of experience in small-to-mid cap biotech equity research and capital markets at independent Canadian investment banks. Over the years, she has conducted numerous comprehensive company and industry analyses in the biotech, life sciences and special situations sectors, assisted in financing early and mid-stage companies, and communicated investment ideas and recommendations primarily to institutional clients in North America and Europe. Most recently Dr. Chen was a respected Biotechnology and Health Sciences Analyst at Loewen, Ondaatje and McCutcheon Limited. She also brings over nine years of experience in academic scientific and medical research. Dr. Chen holds a PhD in Pharmaceutical Sciences from the University of Toronto, with a focus in carcinogenesis and reproductive toxicology, and an Honours BSc in Biochemistry from McMaster University.
*NB: Dr. Chen is currently on maternity leave